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Abstract
Recently mutations in the MYH gene have been associated with a milder form of adenomatous polyposis which
is characterized by a variable level of colonic polyps ranging from a few to several hundred. In the context of
HNPCC it is not unusual to identify patients with a smattering of polyps. The MYH gene product is involved in
DNA repair and indeed the hMSH2/hMSH6 complex (both genes being essential elements of the DNA mismatch
repair pathway) is required to stimulate MYH activity. We reasoned that because of the clinical similarity of
a subset of HNPCC patients to those described with MYH mutations and the role of the hMSH2/hMSH6 complex
in the activation of MYH protein that MYH mutations may account for a small proportion of HNPCC patients.
In a study of 442 HNPCC patients we identified MYH mutations at the same frequency as that expected in the
general population. Nevertheless, two HNPCC families were identified harbouring biallelic changes in MYH. 
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Introduction
Hereditary Non Polyposis Colorectal Cancer
(HNPCC) is an autosomal dominant inherited disorder
associated with a familial predisposition to colorectal
cancer (CRC). It is characterised by early age of
disease onset, neoplastic lesions with microsatellite
instability (MSI) and an increased incidence of
extracolonic malignancies such as cancers of the
endometrium, ovary, stomach, small bowel, ureter and
renal pelvis [1]. Approximately 20% of all CRC cases
display familial inheritance [2] however familial
colorectal cancer syndromes, that include HNPCC
and FAP account for around 3% of all colorectal
cancer patients [3]. A significant number of cases that
appear to be inherited therefore do not have mutations
in known genes involved in familial cancer syndromes.
HNPCC has been found to be associated with hMLH1
and hMSH2 genes involved in the mismatch repair
(MMR) pathway. Germline mutations in hMLH1 and
hMSH2, the main causes of mismatch repair
deficiency, have been linked with a significantly
increased risk for developing HNPCC [4, 5]. Among
all HNPCC patients only 80% of men and 40% of
women that have germline mutations in MMR genes
develop CRC [6, 7] and a further 25-50% of women
develop endometrial cancer [8]. MMR gene mutations
do not account for all CRC cases in HNPCC since
some patients fit the clinical criteria for HNPCC yet
they do not harbour a MMR gene mutation. Therefore,
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it is highly likely that there are other genes involved in
the aetiology of HNPCC. 
MYH has recently been identified as an autosomal
recessive inherited form of colonic polyposis. It functions
to repair DNA damage caused by reactive oxygen species
through the DNA repair process known as base excision
repair (BER). MYH removes adenines misincorporated
into DNA opposite guanine or 7,8-dihydro-8-oxo-
-guanine to prevent G:C to T:A mutations (for review see
[9]). Al-Tassan et al [10] were the first to describe the role
of MYH in colorectal polyposis and since then a number
of studies have confirmed this association [11-17]. The
results obtained in these studies suggest that colorectal
cancer and in particular HNPCC might not only be
confined to mutations in MMR genes but also to other
genes involved in DNA repair such as MYH. 
Two known polymorphisms in MYH, Y165C and
G382D, are functionally compromised in the variant
form. Al-Tassan et al [10] demonstrated that the variant
forms of these proteins reduced the glycosylase ability
of the proteins to remove DNA damage caused by
reactive oxygen species (8-oxoG:A). A study by Jones
et al [15] showed that biallelic nonsense and missense
mutations in MYH were found in colorectal cancer
patients that were unrelated and in addition they
identified that sequence variants are found in different
ethnic groups that include the Caucasian (Y165C,
G382D), Indian (E466X), Pakistani (Y90X) and the
Italian (1395delGGA). It is not currently known whether
MYH mutations in the heterozygous form cause CRC
or if they modify the effects of genes already associated
with CRC such as APC, hMLH1 or hMSH2. The study
performed by Kairupan et al [11] demonstrated that
MYH mutations Y165C, G382D and 1391delAGG
were not present in the APC mutation positive FAP
population which suggests that MYH is not a modifier
gene in FAP. 
It has recently been shown that the hMSH2/hMSH6
heterodimer formed as part of the MMR process
functions to stimulate the activation of MYH thereby
linking two DNA repair processes and implying
a connection of MYH to HNPCC [18]. Gu et al [18]
suggest that hMSH proteins and MYH have
a combined effect to remove any DNA damage that
occurs. They have shown a direct interaction between
the hMSH2/hMSH6 heterodimer between hMSH6 and
MYH at residue 232-254 of MYH. Mutant MYH has
also been shown to have a decreased ability to
recognize and repair mismatches that occur due to
reactive oxygen species (ROS). Additionally, Gu et al
[18] showed that MSH2 defective cells have an
impaired function in oxidative damage. This shows
that MSH2 and MYH both have roles in the removal
of oxidative damage. They suggest that this interaction
must be studied further to determine whether the
mutant forms of MYH disrupt the MMR and BER
pathways in colorectal tumourigenesis. Single nucleotid
polymorphisms (SNPs) found in MYH could potentially
interfere with these protein-protein interactions thereby
hindering the ability of MMR and BER pathways to
remove DNA damage and consequently promoting
colorectal cancer [12]. 
Kambara et al [13] suggest that there are a number
of other tumour suppressors on chromosome 1p since
microsatellite stable (MSS) colorectal tumours often
show loss of heterozygosity (LOH) on chromosome 1,
however LOH of chromosome 1 is not usually evident
within patients that have high microsatellite instability
(MSI-H) tumours. MSI-H tumours are usually associated
with HNPCC. This suggests that dysfunction of tumour
suppressors on chromosome 1 might display a different
phenotype to that of HNPCC (microsatellite stabile
[MSS] but a small number of adenomas). 
In the current study, we have investigated a series
of patients that have been extensively screened for
hMLH1 and hMSH2 germline mutations by denaturing
high performance liquid chromatography (dHPLC)
analysis, denaturing gradient gel electrophoresis
(DGGE), direct sequencing and multiplex ligation probe
amplification (MLPA) analysis. Using this screening
strategy, two groups of patients were identified: patients
with a confirmed germline mutation in hMLH1 or
hMSH2, and patients that were mutation negative.
These two groups were assessed for the presence of
the two common MYH mutations (Y165C and G382D)
to determine whether patients that manifest the clinical
characteristics of HNPCC harbour these mutations. 
Methods
Patients
Patients were selected from across the State of New
South Wales because they fulfilled the clinical criteria
of Hereditary Non Polyposis Colorectal Cancer
(HNPCC). All patients enrolled in this study had given
informed consent for their anonymous DNA to be used
for research into genetic predispositions to colorectal
cancer. This study was carried out with the approval of
the Hunter Area and the University of Newcastle’s
Research Ethics Committees. 
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Table 1. Genetic alterations identified in the MYH gene and disease characteristics of the patients
Patient HNPCC First Second Sex Age of Number CRC Other
Number MMR Alteration Alteration Diagnosis of Adenomas (Age of Diagnosis) Cancers
Mutation of Adenomas
1 NO Y165C NO F 43 1 N-AF
2 NO G382D V22M F >30 ? AF (36) 
3 hMSH2 (P)* G382D NO M 46 3 AF (46) Melanoma (42) 
4 NO G382D NO M >70 ? N-AF Gastric (78) 
5 hMSH2 G382D NO M >30 ? N-AF
6 NO G382D V22M F >40 ? AF (47) 
7 NO G382D NO F 45 1 N-AF
* hMSH2 polymorphism with an unknown functional consequence
The patients involved in this study fulfilled either the
Amsterdam or Bethesda HNPCC criteria. This study
included patients from families that fit the clinical criteria
for HNPCC even though they might not have
developed disease nor had a mutation in hMLH1 and
hMSH2. Three groups of patients were used in this
study. Group 1 consisted of 233 patients of which 162
patients were affected with CRC who were shown not
to harbour germline mutations in the hMLH1 and
hMSH2 genes by denaturing high performance liquid
chromatography (dHPLC) analysis followed by direct
sequencing, the multiplex ligation probe amplification
(MLPA) assay and denaturing gradient gel
electrophoresis (DGGE). This group of patients was
collected from 1997 to 2004. Group 2 consisted of
209 patients that had a confirmed mutation in either
hMLH1 or hMSH2. This group of patients was collected
from 1997 to 2004. Group 3 (control group) consisted
of a series of 296 anonymous control DNA samples
collected between the years of 1993 and 1997 with
a mean age of 51 years (range 30-94). 
DNA isolation
Genomic DNA was isolated from Na2EDTA blood
according to the method previously described by Miller
et al [19]. 
Real Time PCR (RT-PCR) SNP genotyping
DNA samples were SNP genotyped to determine
the allele frequency of the two common MYH
mutations, Y165C and G382D. Allelic discrimination
was performed on an ABI PRISM® 7900HT sequencing
detection system (PE Applied Biosystems, Foster City,
USA). Assay-by-DesignSM, a service that is offered by
Applied Biosystems (PE Applied Biosystems, Foster City,
USA), was used to design primers and probes. The
assay functions under universal reactions and
conditions with each reaction containing: 50ng DNA,
0.125µl 40x Assay Mix, 2.5 µl Taqman® Universal PCR
master mix made up to 5 µl with sterile MilliQ water.
The thermal cycling conditions were: 50oC for
2 minutes, 95oC for 10 minutes, and 40 cycles of 92oC
for 15 seconds and 60oC for 1 minute. Post PCR, the
plate was scanned to allow discrimination between the
different genotypes. 
Primer and probe sequences
The primers and probes used for genotyping both




Wild type probe VIC–CTGGGCTACTATTCT
Mutant probe FAM–TGGGCTGCTATTCT
G382D
Forward 5’ – GACCCCTGCCTGGCT
Reverse 5’ – GACGGGAACTCCCACAGT
Wild type probe VIC – CCTCTCAGGTCTGCTG
Mutant probe FAM – CCTCTCAGATCTGCTG
DNA sequencing of the MYH gene
All patients who were determined to be heterozygous
for either Y165C or G382D polymorphisms were further
investigated for additional mutations in the MYH gene.
Primers designed by Kairupan et al [11] were used for
this analysis. 
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DNA analysis was performed using a semi-
automated sequencing unit (model 310, Perkin-Elmer
Applied Biosystems Division, Foster City, USA)
according to the manufacturer’s instructions. All
germline mutations identified were confirmed by
reverse sequencing. The sequence variant position in
the MYH gene was compared to that on the NCBI
database, accession number BC003178.1.
Statistics
Differences in allele frequency between groups were
determined by chi-squared analysis. Statistical
differences were assessed using the STATA statistical
package (STATA Corporation, College Station TX); p
values less than 0.05 were considered significant. 
Results
In total, 442 HNPCC patients were assessed for
the presence of two MYH polymorphisms, Y165C and
G382D. The frequency of the mutations in the entire
HNPCC group compared to the controls was not
significant (p=0.798). 
In the control group of 296 patients, the G382D
mutation was found at a frequency of 1.35% and the
Y165C mutation was not found in any of the controls.
The frequency observed in the control population is
consistent with the observed frequency in other
populations studied. 
In group 1 (mutation negative), of the 233 patients,
1 was heterozygous for the Y165C mutation and 4 were
heterozygous for the G382D mutation. The frequency
of the mutations in this group was not significantly
different as compared to group 2 (p=0.317) or the
control population (p=0.483). 
In group 2 (mutation positive), of the 209 patients,
2 were heterozygous for the G382D mutation. One
patient had a confirmed causative mutation in hMSH2
and the other had 2 polymorphisms, one of which was
non-causative as judged by information on the Insight
mutation database (www.insight-group.org) and the other
was an unknown functional variant (1661+12A>G and
1551-9T>A, respectively). The polymorphism in intron
9 is close to the intron-exon boundary of intron 9 and
exon 10 and therefore could possibly have a detrimental
functional consequence. The frequency of the mutations
in this group was not significantly different as compared
to the controls (p=0.687). 
The DNA of all patients that were heterozygous for
Y165C and G382D was further analysed to determine
whether any other mutations were present. Two of the
seven patients were heterozygous for the G382D
polymorphism, harboured the causative mutation
V22M. No other changes were found. 
Discussion
Identifying genes involved in colorectal cancer
remains a challenge since known mutations in inherited
disorders only account for approximately 2-5% of all
CRC cases [5]. A large proportion of CRC cases that
appear to have Mendelian dominant inheritance,
however, have an unknown genetic cause of disease.
It has been suggested that inherited predispositions to
CRC are possibly due to low-penetrance genetic
variants clustered at many loci [20]. 
In our study, we evaluated the two common MYH
polymorphisms in the Caucasian population, Y165C
and G382D, which are associated with an increased
risk for developing CRC, in an Australian series of
HNPCC patients. The MYH polymorphisms studied
previously have been found in 1% of the general
population and the findings in the current study confirm
this result since 1.35% of the control population was
heterozygous for MYH mutations, all were heterozygous
for G382D. 
In total 7 HNPCC patients were heterozygous for
1 of the 2 polymorphisms in MYH (1.6%). Five of the
patients were from the sub-population of HNPCC
patients who were shown not to harbour mutations in
the DNA mismatch repair genes hMSH2 or hMLH1.
This accounts for approximately 2% of the HNPCC
mutation negative population. Of the five MYH
mutation carriers, one patient was heterozygous for
Y165C and four patients were heterozygous for
G382D. Direct sequencing of the MYH gene revealed
that two of them harboured the V22M mutation, which
has been previously identified [11, 13, 21, 22].
Kairupan et al [11] showed that 1 patient heterozygous
for the Y165C mutation also harboured the V22M
polymorphism. Together, the evidence suggests that
the V22M polymorphism could be an additional
common MYH polymorphism associated with
colorectal cancer. The suggestion that there are other
common MYH polymorphisms associated with
colorectal cancer needs to be verified in a much larger
study. In the remaining 5 patients no evidence of
a second mutation was forthcoming but the possibility
remains that mutations could be present in the
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promoter region of MYH. Alternatively, exon deletions
cannot be ruled out as these were not investigated. 
Approximately 1% of the HNPCC mutation positive
population carried the MYH mutations. Two patients
that were heterozygous for the G382D mutation
harboured hMSH2 mutations, one of which has not
been functionally evaluated. This is the first study to
describe the existence of MYH polymorphisms in
association with MMR mutation positive patients. This
is an interesting finding since the MMR heterodimer
hMSH2/hMSH6 interacts directly with MYH through
hMSH6 to stimulate DNA binding and glycosylase
activity to remove mismatches caused by reactive
oxygen species (ROS) which are the most prevalent
source of DNA damage in aerobic organisms [12, 18].
A previous study suggests that MYH does not initiate
progression of cancer but it acts as a promoter [13]. 
In a previous study, Kairupan et al [11] found that
the MYH mutations, Y165C and G382D, were not
represented in FAP APC mutation positive patients
suggesting that MYH does not play a modifying role in
APC driven FAP. Interestingly, this study shows that MYH
mutations could possibly modify the functionality of the
heterodimer hMSH2/hMSH6 since two patients with
mutations in hMSH2 were also heterozygous for MYH
(G382D) mutations. 
In addition, MYH mutations were found in the
HNPCC MMR mutation negative group. This result
suggests that MYH may account for some of the cases
of CRC where no genetic predisposition has been
identified. In a previous study we have shown that the
clinical features of some of the patients harbouring
MYH mutations are similar to HNPCC patients [11]. In
this study, we found that from the clinical information
available on each patient only a few adenomas were
identified in patients harbouring mutations in MYH. 
Similar to Kairupan et al [11], in the HNPCC
population studied herein there was no overrepresentation
of extracolonic cancers apart from one patient diagnosed
with melanoma and another with gastric cancer. Together
the evidence suggests that upper gastrointestinal
malignancies might not be a feature of this type of
colorectal cancer predisposition. 
In conclusion, the results of our study show that
MYH is associated with colorectal cancer risk and can
possibly be associated with the clinical features of
HNPCC. This finding may aid in screening individuals
at risk of developing CRC. In addition, there remains
the possibility that other MYH mutations common in
the Australian population may indeed modify colorectal
cancer risk in an otherwise high-risk population. 
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